McDonald, C., Uy, J., Hu, W., Wirtz, V., Juethner, S., Butcher, D., . . . Moyle, G. (2012). Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. Mary Ann Liebert, Inc.

McDonald, Cheryl, Jonathan Uy, Wenhua Hu, Victoria Wirtz, Salome Juethner, David Butcher, Donnie McGrath, Awny Farajallah, i Graeme Moyle. Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated With Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. Mary Ann Liebert, Inc, 2012.

McDonald, Cheryl, et al. Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated With Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. Mary Ann Liebert, Inc, 2012.